TickerTalks
Browse all tickers →
TickerTalks›$NAUT
NANAUT

Nautilus Biotechnolgy, Inc.

$NAUT·$215M·Biotechnology·Healthcare
$0.99-2.4%YTD-49.2%1Y+33.0%
Mentions · last 7 days
2026-07-29: 9 posts2026-07-30: 2 posts2026-07-31: 21 posts2026-08-01: 2 posts2026-08-02: 0 posts2026-08-03: 7 posts2026-08-04: 3 posts450%
Price updated 4h ago·X counts updated 4h ago
NANAUT
$NAUTNautilus Biotechnolgy, Inc.
$0.99-2.45%45 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NAUT, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-08-03

Falling on heavy selling — points lower unless it turns around.

Nautilus Biotechnology is the proteomics-platform micro-cap at 10%-of-range — Q2 -35% drop on the broadscale platform delay is the specific reset.

Nautilus Biotechnology Inc. is a specific US-listed proteomics-platform development-stage franchise — proprietary technology for quantifying and unlocking proteome complexity. Up 1% today, down 47% year to date, but up 29% over 12 months, sitting at just the 10th percentile of the 52-week range on a post-earnings breakdown tape.

Where it stands after Q2:

  • The revenue base is zero with severe unit economics: reported quarters at $0 revenue with EPS -$0.11, -$0.11, -$0.12 — the specific pattern of a pre-commercial franchise where the entire enterprise value reflects platform-conviction plus balance-sheet cash.
  • The valuation math is speculative: TTM P/E of -5 (loss-making), price-to-sales undefined on zero revenue. Analyst estimates model FY26 revenue of $500K rising to FY27 revenue of $6.1M with EPS staying around -$0.50 — the specific pattern of a franchise where the reset year confirms multi-year burn.
  • The specific broken-story catalyst: shares fell -35% after the company hit a first-revenue commercial milestone but disclosed a major broadscale platform delay that crushes the long-term thesis. One bear summarizes it as practically uninvestable as of the earnings week — the specific pattern of a franchise where the platform-delay overshadows the first-revenue milestone.
  • The governance signal is specific: the June 30 SC 13D/A from AH Bio Fund II disclosed 8,366,966 shares — the specific pattern of a franchise where the institutional-anchor holder is maintaining exposure through the reset.

The next quarterly print needs dated commentary on the broadscale-platform-delay revised timeline plus continued first-revenue conversion to arrest the breaking-down tape; another platform-delay disclosure or a cash-runway walk-back would take the stock through the 10%-of-range low — the specific risk for a pre-commercial franchise where the whole tape has priced significant broken-story impairment.

Agrees with X sentimentX is bearish and I agree with the honest read — the -35% Q2 drop on the broadscale platform delay plus the practically-uninvestable framing is a real broken-story pattern. The bull reservation to name for a contrarian view is that the AH Bio Fund II institutional anchor plus first-revenue milestone are real anchors if the revised platform timeline lands.

What to watch: The next quarterly print — good = dated commentary on the broadscale-platform-delay revised timeline with continued first-revenue conversion; bad = another platform-delay disclosure or a cash-runway walk-back, which takes the stock through the 10%-of-range low.

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bearish sentiment5 posts analyzed · as of 2026-08-04

Nautilus Biotechnology chatter is downbeat after Q2. The stock is down 35% on the print — first ever revenue at $0.2M is undercut by a major broadscale platform delay that 'crushes the long-term thesis.' Posters call NAUT 'practically uninvestable as of earnings this week.' A couple of thoughtful posts push back with an updated go-to-market plan analysis, but the mood is dominated by capitulation. Little bullish voice in this window.

Read the AI verdict + X sentiment for $NAUT

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Building single-molecule proteomics instruments to quantify every protein in a cell at scale—pre-revenue platform.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NAUT.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $NAUT

Partial — Building single-molecule proteomics instruments to quantify every protein in a cell at scale—pre-revenue platform; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+40.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-37.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-17.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-35.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 28, 2026$-0.11$-0.14+18.5%
Q1 2026Apr 28, 2026$-0.12$-0.14+17.2%
Q4 2025Feb 26, 2026$-0.11$-0.14+21.4%
Q3 2025Oct 27, 2025$-0.11$-0.15+26.7%
Next earningsTue, Oct 27·consensus EPS $-0.14

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.12$-13.6M
Q4 FY25$0———$-0.11$-12.6M
Q3 FY25$0———$-0.11$-11.5M
Q2 FY25$0———$-0.12$-13.7M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$500K$465K – $535K-$0.51-$0.53 – -$0.482
FY27$6.1M$4.8M – $7.4M-$0.52-$0.63 – -$0.412
FY28$23.8M$22.1M – $25.5M-$0.42-$0.46 – -$0.381
FY29$53.5M$49.7M – $57.3M-$0.38-$0.41 – -$0.351
FY30$98.0M$91.1M – $104.9M-$0.30-$0.33 – -$0.271

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.11%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-49.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-54.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 55.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.815-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 2Ah Equity Partners Bio Ii, L.l.c.10% owner5.0M sh$11.8MBuyMar 4Sujal M PatelCEO25.0K sh$65K
+ 12 other (12 awards) in window

See when $NAUT insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentJun 30SC 13D/A
AI summary

AH Bio Fund II, L.P. filed an amended Schedule 13D for Nautilus Biotechnology (CUSIP 63909J108), disclosing 8,366,966 shares with sole voting and dispositive power. Amendment to a previously disclosed 5%+ biotech fund position.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

Delaware 001-39434 98-1541723 disclosed voting results from its annual or special meeting. Nautilus Biotechnology, Inc. (the “Company”) held its 2026 annual meeting of stockholders on June 17, 2026 (the “Annual Meeting”). Of the 127,078,855 shares of the Company’s common stock outstanding as of the record date of April 20, 2026, 85,002,191 shares were represented at the Annual Meeting, either by proxy or by attending the meeting. The matters voted on at the Annual Meeting and the votes ...

SC 13D/AActivist amendmentJun 4SC 13D/A
AI summary

Amendment No. 1 to Schedule 13D filed by AH Bio Fund II, L.P. reporting beneficial ownership of Nautilus Biotechnology, Inc. representing a 8% stake (0 shares), with investment intent. This SC 13D/A filing dated 2026-06-04 updates the holder's position and disclosed intentions.

SC 13D/AActivist amendmentMar 4SC 13D/A
SC 13D/AActivist amendmentMar 4SC 13D/A
+ 10 other (3 earnings 8-Ks · 2 10-Qs · 2 proxys · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullbackseekingalpha.com·2d agoNautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcriptseekingalpha.com·8d agoNautilus Biotechnology Q2 Earnings Call Highlightsmarketbeat.com·8d agoNautilus Biotechnology Reports Second Quarter 2026 Financial Resultsglobenewswire.com·8d agoNautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026globenewswire.com·28d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$REGN$IBRX$CAPR$HALO$AURA$ABCL$MRNA
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport